DOCSLIB.ORG

Giant Fibroadenoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Giant Fibroadenoma International Journal of Transplantation & Plastic Surgery ISSN: 2639-2127 MEDWIN PUBLISHERS Committed to Create Value for researchers Case Presentation: Giant Fibroadenoma Tamayo Carbon AM, Vila Garcia E*, Gaitan Garcia CA, Alatorre Aguirre CA and Bencosme Escarraman YY Case Report Surgical Hospital Hermanos Ameijeiras, Cuba Volume 4 Issue 1 Received Date: January 08, 2020 *Corresponding author: Eyleen Vila Garcia, Assistant Professor, Services of Plastic Surgery Published Date: February 14, 2020 and Caumatology and General Surgery, Surgical Hospital Hermanos Ameijeiras, Havana City, DOI: 10.23880/ijtps-16000139 Cuba, Tel: 53232327; Email: [email protected] Abstract Fibroadenomas are benign lesions of the breast, very frequent, composed of glandular and stromal tissue. They are more frequent in women from 20 to 39 years of age, although they can appear in women of any age. It is considered as a giant fibroadenoma if it reaches a size greater than 5 cm or a weight greater than 500gr. Wean enlarged analyze aleft case breast; of a 36-year-old Trucut biopsy female is performed, patient who reporting comes tolipoma, the clinic so breast for presenting reconstruction breast is asymmetry performed at with the stents.expense The of transoperative finding was a giant tumor, performing its exeresis. The histological result reports breast fibroadenoma with fociestablish of hyalinization the correct and diagnosis. foci of fatty infiltration. It can be affirmed that breast pathology should always be studied in detail to Keywords: Fibroadenoma; Benign Tumors; Breast Tumors Introduction between the ages of 20 and 35 [4]. The most frequent clinical presentation is the presence of a palpable nodule or mass, Breast asymmetry is one of the most frequent reasons followed by pain as a second symptom. About 5-10% of these for consultation in plastic surgery. The difference can be in masses or nodules are diagnosed as malignant tumors, within shape, size, position and projection. When the difference in Fibroadenomawhich infiltrating is ductal usually carcinoma small isand the mostcan common.be treated volumeBenign exceeds breast 100cc pathology it is called includes: anisomastia. tumors, trauma, conservatively; Only between 0.5 and 2% of these lesions abscesses, mastitis, cysts, among others. The diagnosis should be as early as possible, as well as its treatment because certain benign diseases have increased the risk of deformitieswill grow rapidly. and increased Giant fibroadenomas, suspicion of malignancy,larger than which5 cm malignancy. isor greaterwhy they than usually 500 gr require [1-5], are surgical associated treatment with significant [1]. The Benign breast tumors have an incidence of 86.69%. Of previously suspected by the clinic and by images. You should alwaysdiagnosis rule is out made virgin exclusively breast hypertrophy by biopsy, and although the Phylodes it is 85% of cases. The Fibroadenoma is a common benign tumor that have similar behaviors but different treatments. breastthese, thelesión fibroadenoma [1-3], which is typically the most occurs common, in young representing patients Case Presentation: Giant Fibroadenoma Int J Transplant & Plastic Surg 2 International Journal of Transplantation & Plastic Surgery Case Report delimited, lobed, 15 cm in diameter, with a weight of 850 gr A 36-year-old female patient who attended the (Figure 3). left breast that began in her teens. He has a personal history ofconsultation bronchial asthma, due to the without increase medication, in size and allergy asymmetry to penicillin of the left,and lowazithromycin. implantation, On physicalwide base, examination, upper empty asymmetry pole on the of rightthe breasts side, descending is observed below at the the expense submammary of enlargement groove of3 cm,the nipple areola complex without alterations (Figure 1). Figure 3: The histopathologicalThe transoperative report was a findings.tumor with foci of dense collagen and epithelium without atypia or evidence of hyalinization and fatty infiltration, consisting of stroma, malignancy (Figure 4). Figure 1: Asymmetry of the left breast. palpated, with smooth surface, regular edges, not painful and movable.In the left breast, a tumor of approximately 4 x 9 cm is Breast ultrasound and trucut biopsy are performed that report adipose tissue suggestive of lipoma (Figure 2). Figure 4: The histopathological tumor. The patient evolved without complications and the immediate postoperative period was satisfactory in terms of symmetry, scarring and aesthetic results (Figure 5). Figure 2: Breast ultrasound suggestive of lipoma. and remodeling of the breast tissue with the placement of siliconeGiven the stents situation for correction described, of the asymmetry excision of isthe decided. lipoma Figure 5. Immediate postoperative. The transoperative findings were: left breast tumor, well Vila Garcia E, et al. Case Presentation: Giant Fibroadenoma. Int J Transplant & Plastic Surg 2020, Copyright© Vila Garcia E, et al. 4(1): 000139. 3 International Journal of Transplantation & Plastic Surgery Discussion adequate follow-up in search of future breast masses. Benign breast tumors are common, with giant The reported case had as its main symptom the increase in volume of the breast with rapid growth, which can be breast asymmetry in women between the ages of 20 alarming for women. Although the patient’s priority is to andfibroadenomas 35 [6]. The being cause the of mostthese common large masses cause isof unknown.unilateral improve her body’s self-image, the plastic surgeon must Hormones can play an important role, because these focus not only on the challenge of obtaining a good aesthetic lesions occur frequently in puberty, pregnancy and with result but also on the correct diagnosis to maintain and raise oral contraceptives [7]. Although they are benign, giant the patient’s biopsychosocial well-being status and quality of life. duefibroadenomas to the rapid can growth compress of surroundingan encapsulated tissue tumor and alter[8]. Fibroadenomathe lobular structure is a painless, by increasing solitary size and and unilateral vascularization; growth cause of breast asymmetry in young patients. For all the above, we conclude that giant fibroadenoma is a in 3 to 6 months to reach 20 cm in diameter, which distorts It is recommend the application of the Breast Cancer mass, with no evidence of infection and can double in size the shape of the breasts In addition, when they are complex women,Early Detection annual ProgramMastology (effective consultation in Cuba for since those 1989) over for30 thefibroadenomas risk of developing they can havebreast histological cáncer changes such as yearsall women, of age whichand mammography includes: breast for thoseself-examination over 40 years for and all cysts, calcifications and apocrine changes that can increase more; to ensure early detection and proper treatment of malignant processes such as: ulceration and[9]. inversion Superficial of breast diseases. themanifestations nipple [10]. ofEarly giant detection, fibroadenomas diagnosis can and be treatment similar toof References fibroadenomas should be performed early to minimize the 1. risk of complications. The diagnosis of fibroadenomas is alwaysmade with be distinguisheddetailed physical from examination, phylodes tumor breast and ultrasound virginal Kalim M, Ahmad S, Ozair F (2018) Frequency of and trucut biopsy or fine needle aspiration [11]. It should fibroadenoma in patients presenting with breast lump. that accounts for 0.3-0.9% of mammary neoplasms and, 2. J Postgrad Med Inst 32 (1): 95-98. althoughhypertrophy. it usuallyThe phylodes appears tumor after is thea fibroepithelial fourth decade, tumor in Guzman M, Heron S, Ramos P (2011) Giant breast 8% of cases it develops in women under 20 years of age. 3. Fibroadenoma. Clin Invest Gin Obst 38(1): 32-34. old. The histological characteristics that differentiate it Hidalgo J, Aznar I, Fernandez A 2011) Recurrent juvenile giant fibroadenoma mastectomy. Prog Obstet Ginecol takingfrom fibroadenomas into account that are its not clinical well and defined, ultrasound which behavior causes 4. 54(10): 528-531. candifferential be very diagnosissimilar. Virginal to be very hypertrophy, difficult on also many called occasions, juvenile gigantomastia, is a rare benign condition that causes Corredor B, Marquez M, Lobo F (2011) Giant breast fibroadenoma in adolescents: diagnostic-therapeutic clinical, ultrasound and histological diagnosis is very similar 5. procedures. Clin Invest Gin Obst 38(1): 48-54. toexcessive that of Fibroadenomaand diffuse growth [12]. of one or both breasts whose 616-620.De la Garza O, Days V, Paz M (2018) Giant juvenile In the presented patient, a preoperative trucut biopsy fibroadenoma: case report. Ginecol Obstet Mex 86(9): was performed, which reported adipose tissue, so that 6. surgical treatment for asymmetry correction was decided, Jayasinghe Y, Simmons P (2019) Fibroadenomas in 7. adolescence. Curr Opin Obstet Gynecol 21(5): 402-406. in children and adolescents. Pediatric Clin North Am 36: with the transoperative finding of the tumor described above. Even though in most cases the tumor is palpable and 601-638.Greydanus D, Parks D, Farrell E (2017) Breast disorders 8. familywell defined, history there of nodules is a possibility or breast that cancer it may and be had presented a giant as a transoperative finding. The patient presented had no 451-461.Park C, David L, Argent L (2006) Breast Asymmetry: tumor and breast reconstruction with stents
Load more

Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Olanzapine-Induced Hyperprolactinemia: Two Case Reports
    CASE REPORT published: 29 July 2019 doi: 10.3389/fphar.2019.00846 Olanzapine-Induced Hyperprolactinemia: Two Case Reports Pedro Cabral Barata *, Mário João Santos, João Carlos Melo and Teresa Maia Departamento de Psiquiatria, Hospital Prof. Dr. Fernando da Fonseca, EPE, Amadora, Portugal Background: Hyperprolactinemia is a common consequence of treatment with antipsychotics. It is usually defined by a sustained prolactin level above the laboratory upper level of normal in conditions other than that where physiologic hyperprolactinemia is expected. Normal prolactin levels vary significantly among different laboratories and studies. Several studies indicate that olanzapine does not significantly affect serum prolactin levels in the long term, although this statement has been challenged. Aims: Our aim is to report two olanzapine-induced hyperprolactinemia cases observed in psychiatric consultations. Methods: Medical records of the patients who developed this clinical situation observed Edited by: in psychiatric consultations in the Psychiatry Department of the Prof. Dr. Fernando Angel L. Montejo, Fonseca Hospital during the year of 2017 were analyzed, complemented with a non- University of Salamanca, Spain systematic review of the literature. Reviewed by: Carlos Spuch, Results: The case reports consider two women who developed prolactin-related Instituto de Investigación Sanitaria symptoms after the initiation of olanzapine. No baseline prolactinemia was obtained, and Galicia Sur (IISGS), Spain Lucio Tremolizzo, prolactin serum levels were only evaluated after prolactin-related symptoms developed: University of Milano-Bicocca, Italy at the time of its measurement, both patients had been taking olanzapine for more *Correspondence: than 24 weeks. Hyperprolactinemia was found to be present in Case 2, whereas Case Pedro Cabral Barata 1 (a 49-year-old woman) had “normal” serum prolactin levels for premenopausal and [email protected] prolactin levels slightly above the maximum levels for postmenopausal women.
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • 1 Evidence Tables for Mastitis, Abscess and Related Conditions And
    Evidence tables for mastitis, abscess and related conditions and issues Tabulation of studies on mastitis illustrates the heterogeneity of study design, definition of mastitis, and factors investigated. Recent studies on mastitis in Western populations have been included, with some older studies of particular interest. List of tables: Table A: Incidence and treatment of Mastitis Table B: Reviews of the literature Table B1: Core Reviews Table B2: Other review sources Table B3: Further reviews Table C: Women’s experience of mastitis Tables D: Abscess Table D1: Incidence of abscess Table D2: Interventions for abscess Table E: Overabundant milk supply Table F: Chronic breast pain Table G: Mastitis and breast augmentation Table H: Alternative treatments for mastitis Table I: Physiology of mastitis during lactation Table J: Role of specific pathogens Table J1: Role of Staphylococcus aureus in mastitis Table J2: Mastitis and MRSA Table J3: MRSA mastitis and abscess case study Table J4: Role of Corynebacterium Table K: Effects on the baby Table K1: Effects of mastitis on the baby Table K2: Antibiotic treatment of women during lactation – effects on the infant Table K3: Maternal Strep B infections and effects on the baby through breastfeeding. Table L: Prevention 1 Table A: Incidence and treatment of Mastitis: Factors associated with incidence (possible risk factors); also studies of treatment experienced by women with mastitis: Author Type of Definition of Outcomes measured Results Comments date study mastitis Scott 2008 Prospective Red, tender, hot, Incidence of mastitis, 18% (95% CI 14%, 21%) had at least one 72% of women longitudinal swollen area of the reoccurrence, timing of episode of mastitis invited to take UK cohort study breast accompanied by episodes.
    [Show full text]
  • Breast Disorders in Girls and Adolescents. Is There a Need for a Specialized Service?
    Original Study Breast Disorders in Girls and Adolescents. Is There a Need for a Specialized Service? Lina Michala MRCOG, PhD *, Alexandra Tsigginou MD, PhD, Dimitris Zacharakis MD, Constantine Dimitrakakis MD, PhD 1stDepartment of Obstetrics and Gynaecology, University of Athens, Alexandra Hospital, Athens, Greece abstract Introduction: Minor breast concerns in childhood and adolescence are common and lead to increased anxiety among young patients and their families, particularly due to high correlation with breast cancer. However, most breast services aim at managing adults and triaging patients with breast cancer, whereas adolescent medicine specialists or pediatricians are usually not appropriately trained to identify and treat breast pathology. Methods: We reviewed hospital records of all patients attending a pediatric and adolescent gynecology or breast clinic of a tertiary referral hospital, with a breast related symptom, between January 2009 and December 2011. We collected information regarding age at presen- tation, age at menarche, diagnosis, management and outcome. Results: We identified 81 patients of which 11 presented with an abnormal nipple or areolar secretion, 33 had a palpable lump, 20 had mastitis, and 16 had unequal breast development. One patient presented with virginal breast hypertrophy. Three out of 11 of the patients with an abnormal secretion had a cyst identified on ultrasonography. Out of the palpable lumps 12 were fibroadenomas, 3 were phyllodes tumors, and 14 were cystic in nature. The phyllodes tumors and half of the fibroadenomas were removed. The remaining fibroadenomas remain under regular ultrasonographic follow-up. All cases of mastitis were treated conservatively and resolved with broad spectrum antibiotic treatment. Conclusion: In our series, no malignancies were identified.
    [Show full text]
  • Cirugía De La Mama
    25,5 mm 15 GUÍAS CLÍNICAS DE LA ASOCIACIÓN ESPAÑOLA DE CIRUJANOS 15 CIRUGÍA DE LA MAMA Fernando Domínguez Cunchillos Sapiña Juan Blas Ballester Parga Gonzalo de Castro Fernando Domínguez Cunchillos Juan Blas Ballester Sapiña Gonzalo de Castro Parga CIRUGÍA DE LA MAMA CIRUGÍA SECCIÓN DE PATOLOGÍA DE LA MAMA Portada AEC Cirugia de la mama.indd 1 17/10/17 17:47 Guías Clínicas de la Asociación Española de Cirujanos CIRUGÍA DE LA MAMA EDITORES Fernando Domínguez Cunchillos Juan Blas Ballester Sapiña Gonzalo de Castro Parga SECCIÓN DE PATOLOGÍA DE LA MAMA © Copyright 2017. Fernando Domínguez Cunchillos, Juan Blas Ballester Sapiña, Gonzalo de Castro Parga. © Copyright 2017. Asociación Española de Cirujanos. © Copyright 2017. Arán Ediciones, S.L. Castelló, 128, 1.º - 28006 Madrid e-mail: [email protected] http://www.grupoaran.com Reservados todos los derechos. Esta publicación no puede ser reproducida o transmitida, total o parcialmente, por cualquier medio, electrónico o mecánico, ni por fotocopia, grabación u otro sistema de reproducción de información sin el permiso por escrito de los titulares del Copyright. El contenido de este libro es responsabilidad exclusiva de los autores. La Editorial declina toda responsabilidad sobre el mismo. ISBN 1.ª Edición: 978-84-95913-97-5 ISBN 2.ª Edición: 978-84-17046-18-7 Depósito Legal: M-27661-2017 Impreso en España Printed in Spain CIRUGÍA DE LA MAMA EDITORES F. Domínguez Cunchillos J. B. Ballester Sapiña G. de Castro Parga AUTORES A. Abascal Amo M. Fraile Vasallo B. Acea Nebril G. Freiría Barreiro J. Aguilar Jiménez C. A. Fuster Diana L.
    [Show full text]
  • Pseudoangiomatous Stromal Hyperplasia of the Breast
    Case Report / Olgu Sunumu J Breast Health 2015; 11: 148-51 DOI: 10.5152/tjbh.2015.2333 Pseudoangiomatous Stromal Hyperplasia of the Breast: Mammosonography and Elastography Findings with a Histopathological Correlation Psödoanjiomatöz Stromal Hiperplazi Bildirilen Kitlenin Mamo-Sonografi ve Elastografi Bulguları Ebru Yılmaz1, Fatma Zeynep Güngören1, Ayhan Yılmaz1, Tuğrul Örmeci1, Gonca Özgün3, Sibel Çağlar Atacan2, İsmail Sinan Duman4 1Department of Radiology, Medipol University Faculty of Medicine, İstanbul, Turkey 2Department of Radiology, Forensic Medicine Institute, İstanbul, Turkey 3Department of Pathology, Medipol University Faculty of Medicine, İstanbul, Turkey 4Clinic of Radiology, Gaziosmanpaşa Taksim Training and Research Hospital, İstanbul, Turkey ABSTRACT ÖZ Pseudoangiomatous stromal hyperplasia (PASH) is a rare benign mesenchy- Psödoanjiomatöz stromal hiperplazi (PASH), memenin benign mezenkimal mal proliferative lesion of the breast. In this study, we aimed to show a case proliferatif hastalıklarındandır. Stromal miyofibroblastların proliferasyonu of PASH with mammographic and sonographic features, which fulfill the sonucu oluşur. Tipik olarak pre ve perimenapozal kadınlarda görülür. Meme- criteria for benign lesions and to define its recently discovered elastography de ağrı şikayetiyle genel cerrahi polikliniğine başvuran kırk dokuz yaşındaki findings. A 49-year-old premenopausal female presented with breast pain in premenapozal kadın hastanın yapılan meme ultrasonografisinde (US) sağ our outpatient surgery clinic. In ultrasound
    [Show full text]
  • Gynaecomastia
    GYNAECOMASTIA Mrs. Preethi Ramesh Senior Nursing Lecturer BGI DEFINITION Gynecomastia: It is a common endocrine disorder in which there is a benign enlargement of breast tissue in males. Pseudogynecomastia: Enlargement of the male breast, as a result of increased fat deposition is called Pseudogynecomastia. Synonymous terms are used like Adipomastia, or lipomastia. GYNECOMASTIA & PSEUDOGYNECOMASTIA PREVALENCE Asymptomatic palpable breast tissue is common in normal males, particularly in the neonate(60%–90%), at puberty (60%–70%), and with increasing age (20%–65%, >50 years). Because of this high prevalence, gynecomastia is considered a relatively normal finding during these periods of life. Gynecomastia is often called physiologic at these ages. CLASSIFICATION SIGNS AND SYMPTOMS Male breast enlargement with rubbery or firm glandular subcutaneous chest tissue palpated under the areola of the nipple in contrast to softer fatty tissue. Milky discharge from the nipple is not a typical finding but may be seen in a gynecomastia individual with a prolactin secreting tumor. The enlargement may occur on one side or both. Males with gynecomastia may appear anxious or stressed due to concerns about the possibility of having breast cancer. An increase in the diameter of the areola and asymmetry of the chest tissue. PATHOPHYSIOLOGY An altered ratio of estrogens to androgens mediated by an increase in estrogen production. An altered ratio of estrogens to androgens mediated by a decrease in androgen production. An altered ratio of estrogens to androgens mediated by a combination of these two factors. Estrogen acts as a growth hormone to increase the size of male breast tissue. The cause of gynecomastia is unknown in around 25% of cases.
    [Show full text]
  • Transdermal Progesterone Therapy in the Treatment of Fibrocystic Breast
    Open Journal of Obstetrics and Gynecology, 2016, 6, 334-341 Published Online April 2016 in SciRes. http://www.scirp.org/journal/ojog http://dx.doi.org/10.4236/ojog.2016.65042 The Influence of Progesterone Gel Therapy in the Treatment of Fibrocystic Breast Disease Milena Brkic1, Svetlana Vujovic2,3, Maja Franic Ivanisevic4, Miomira Ivovic2,3, Milina Tancic Gajic2,3, Ljiljana Marina2,3, Marija Barac2,3, Branko Barac5, Alekasandar Djogo6, Gabrijela Malesevic7, Damir Franic8,9* 1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina 2Clinic of Endocrinology, Clinical Center of Serbia, Belgrade, Serbia 3School of Medicine, University of Belgrade, Belgrade, Serbia 4Clinic of Gynecology and Obstetrics, Clinical Center Serbia, Belgrade, Serbia 5Institute of Reumatology, Belgrade, Serbia 6Clinical Center of Montenegro, Podgorica, Montenegro 7Department for Diabetes with Endocrinology, University of BanjaLuka, Banja Luka, Republika Srpska 8Outpatient Clinic of Obstetrics and Gynecology, Rogaska Slatina, Slovenia 9School of Medicine, University of Maribor, Maribor, Slovenia Received 1 March 2016; accepted 25 April 2016; published 28 April 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract The effect of progesterone therapy on E2/P ratio changes during the luteal phase, and its con- sequences are on mastalgia and cyst, within a fibrocystic breast disease (FBD). Fifty women with FBD were included. Information for mastalgia and mastodynia were checked with a question- naire. All women had (E2) and (P) concentration checked before and during the therapy on the 21st and 24th day of a cycle, ultrasound measured size and number of cysts before and during the therapy.
    [Show full text]
  • Tumour Forming Pseudoangiomatous Stromal Hyperplasia: a Case Report
    International Surgery Journal Vasuki R et al. Int Surg J. 2017 Aug;4(8):2854-2857 http://www.ijsurgery.com pISSN 2349-3305 | eISSN 2349-2902 DOI: http://dx.doi.org/10.18203/2349-2902.isj20173435 Case Report Tumour forming Pseudoangiomatous stromal hyperplasia: a case report Vasuki R., Thanmaran N. B., A. K. Kalpana Devi, Rajesh Menon Moothedath*, Satheesh Kumar M. Department of General Surgery, Government Kilpauk Medical College, Chennai, India Received: 26 May 2017 Accepted: 23 June 2017 *Correspondence: Dr. Rajesh Menon Moothedath, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Tumor-forming Pseudoangiomatous stromal hyperplasia (PASH) is a rather uncommon breast lesion and only very few cases of tumor-forming PASH were reported from 1986, since the lesion was originally described. In contrast, focal, non-tumor forming PASH may be an incidental microscopic finding in up to 23% of breast biopsies. PASH is a benign proliferative lesion of the breast stroma that is characterized by slit-like pseudovascular spaces lined by endothelial-like spindle cells. It is indeed rare for a discrete breast mass to have PASH as the main pathological feature on histopathology. The breast mass, typically unilateral, was usually diagnosed clinically as a fibroadenoma. When found in tumour form, PASH most commonly manifests as a single, circumscribed, palpable mass in a premenopausal female.
    [Show full text]
  • The Relationship Between Maternal Intravenous Fluids and Breast Changes in the Postpartum Period: a Pilot Observational Study
    THE RELATIONSHIP BETWEEN MATERNAL INTRAVENOUS FLUIDS AND BREAST CHANGES IN THE POSTPARTUM PERIOD: A PILOT OBSERVATIONAL STUDY SONYA MYLES RN IBCLC BScN Thesis submitted to the Faculty of Graduate and Postdoctoral Studies In partial fulfillment of the requirements for the Masters Degree in Nursing School of Nursing Faculty of Health Sciences University of Ottawa © Sonya Myles, Ottawa, Canada, 2014 BREAST ENGORGEMENT AND EDEMA PILOT STUDY ii Dedicated to Michael Durbin 25 April 1977 – 12 March 2013 BREAST ENGORGEMENT AND EDEMA PILOT STUDY iii Table of Contents List of Tables..............................................................................................................vii List of Figures........................................................................................................... viii List of Thesis Appendices.......................................................................................... ix Glossary……………………………………………………………………………..x Abstract..................................................................................................................... xii Acknowledgements................................................................................................... xiii CHAPTER 1 - Introduction Introduction…………………………………………………………………..…….. 1 Organization of the Thesis…………………………………………………….…… 1 Background Clinical Issue.................................................................................................. 2 Problem Statement........................................................................................
    [Show full text]
  • Dicionario-Ilustrado-De-Saude.Pdf
    http://materialdeenfermagem.blogspot.com Aabcdefghijklmnopqrstuvwxyz A (1) em fisiologia, serve para representar o símbolo do ar alveolar; em física, é o símbolo do ampère. (2) em hematologia, o grupo sangüíneo A do ABO. (3) segundo som aórtico. a em fisiologia, é o símbolo do sangue arterial, ou ainda, serve para designar a abreviatura de artéria. a termo em obstetrícia, refere-se ao bebê nascido da 38a até a 41a semana de gestação. a-, an- prefixo de negação, afastamento de, não. A, fibra fibras nervosas mielínicas encontradas em nervos somáticos; conduzem impulsos nervosos a uma velocidade que varia de 6 a 120 m/s. aa ou ana- da expressão latina ana partes aequales. Nas receitas médicas, serve para designar a abreviação que é utilizada após duas ou mais substâncias para indicar que elas devem ser dadas em quantidades iguais. aania medo mórbido de perder a capacidade sexual. ab- palavra latina que significa “longe de”. É utilizada como um prefixo que in- dica distanciamento, afastamento, separação. Seu antônimo é o prefixo ad-. abacteriano que não contém bactérias. abacto aborto provocado. Abadie, sinal de espasmo do músculo elevador da pálpebra superior. abaixa-língua instrumento espatulado com que a língua é mantida abaixada para exame ou intervenção cirúrgica. Há vários tipos de abaixa-língua. abalienação distúrbio mental. aba-mordida, radiografia com filme tipo de radiografia que demonstra as co- roas e o terço superior das raízes dos dentes superiores e inferiores. Também denominada radiografia interproximal. abandônico criança ou adulto cujas dificuldades vitais estão centradas em tor- no do temor ou do sentimento, reais ou imaginários, de estar abandonado, de perder o amor de seus pais ou de seus próximos.
    [Show full text]